BCL2L1 and acute lymphoblastic leukemia: Concomitantly, the combination of venetoclax with the dual BCL-XL/BCL-2 inhibitor navitoclax and chemotherapy was assessed in a phase I dose-escalation study in pediatric and adult patients with R/R ALL or LLy [47] (NCT03181126).